ProQR Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions EUR

Scroll to see more
ProQR Therapeutics N.V. income statement - Annual data in millions EUR
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue19.559.533.592.380.000.000.00
Cost of Revenue0.000.00-69.52-59.590.000.000.00
Gross Profit19.559.534.042.381.030.000.00
Operating Expenses
Research & Development36.3625.1550.8742.2238.1446.4929.51
Selling, General & Administrative13.6616.2418.6517.3713.6912.8912.54
Operating Expenses50.0241.3868.7559.5942.3757.6036.68
Operating Income-30.47-31.86-65.16-57.21-42.37-57.60-36.68
Other Income/Expense
Interest Income3.252.590.110.010.310.760.19
Interest Expense-1.081.205.13-3.412.041.080.81
Other Income/Expense0.35-2.916.07-1.88-2.401.310.21
Income
Income Before Tax-27.96-27.81-64.11-60.68-46.49-56.61-37.09
Income Tax Expense-0.20-0.080.100.120.120.130.00
Net Income-27.76-28.12-64.42-60.74-46.57-56.48-36.89
Net Income - Continuous Operations-27.76-27.74-64.20-60.800.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-29.58-23.84-56.46-56.55-42.10-53.48-35.28
EBIT-30.47-26.36-58.98-57.21-44.45-55.53-36.28
Depreciation & Amortization0.892.512.520.662.360.000.00
Earnings Per Share
Basic EPS---1.00-1.00-1.00-1.00-1.00
Diluted EPS---1.00-1.00-1.00-1.00-1.00
Basic Shares Outstanding86.0981.0171.6464.1850.0641.0434.05
Diluted Shares Outstanding86.0981.0171.6464.1850.0641.0434.05